Therapy Detail

Therapy Name LOXO-292
Therapy Description

LOXO-292 is an inhibitor of RET, specifically targeting RET mutations and fusions, and may block the growth of cells with Ret activity (NCI Drug Dictionary).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
LOXO-292 RET Inhibitor 36 LOXO-292 is an inhibitor of RET, specifically targeting RET mutations and fusions, and may block the growth of cells with Ret activity (NCI Drug Dictionary).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
RET M918T thyroid medullary carcinoma sensitive LOXO-292 Preclinical - Cell culture Actionable In a preclinical study, thyroid medullary carcinoma cells harboring RET M918T were sensitive to treatment with LOXO-292 in culture, demonstrating decreased cell proliferation (PMID: 29912274). 29912274
RET M918T Advanced Solid Tumor sensitive LOXO-292 Preclinical - Cell culture Actionable In a preclinical study, cells expressing RET M918T were sensitive to treatment with LOXO-292 in culture, demonstrating decreased cell proliferation (PMID: 29912274). 29912274
RET mutant thyroid medullary carcinoma sensitive LOXO-292 Phase I Actionable In a Phase I trial, LOXO-292 treatment resulted in partial response in 14% (2/14) and tumor reduction in 79% (11/14) of RET mutant thyroid medullary cancer patients (J Clin Oncol 36, 2018 (suppl; abstr 102); NCT03157128). detail...
RET M918T RET V804M thyroid medullary carcinoma sensitive LOXO-292 Clinical Study Actionable In a clinical case study, a patient with thyroid medullary cancer harboring RET M918T and RET V804M demonstrated an initial response to LOXO-292, which included a decrease in allelic fraction of RET M918T and RET V804M over 8 weeks and a radiographic response of nearly 54% post 6.9 months of treatment (PMID: 29912274; NCT03157128). 29912274
RET fusion non-small cell lung carcinoma sensitive LOXO-292 Phase I Actionable In a Phase I trial, LOXO-292 treatment resulted in an objective response rate of 65% (17/26) in RET fusion-positive non-small cell lung cancer patients (J Clin Oncol 36, 2018 (suppl; abstr 102); NCT03157128). detail...
RET C634W thyroid medullary carcinoma sensitive LOXO-292 Preclinical - Cell line xenograft Actionable In a preclinical study, thyroid medullary carcinoma cells harboring RET C634W were sensitive to treatment with LOXO-292, demonstrating decreased cell proliferation in culture and inhibition of tumor growth in cell line xenograft models (PMID: 29912274). 29912274
RET fusion papillary thyroid carcinoma sensitive LOXO-292 Phase I Actionable In a Phase I trial, LOXO-292 treatment resulted in an objective response rate of 83% (5/6) in RET fusion-positive papillary thyroid cancer patients (J Clin Oncol 36, 2018 (suppl; abstr 102); NCT03157128). detail...
RET V804M thyroid medullary carcinoma sensitive LOXO-292 Phase I Actionable In a Phase I trial, LOXO-292 treatment resulted in partial response in a thyroid medullary cancer patientharboring RET V804M (J Clin Oncol 36, 2018 (suppl; abstr 102); NCT03157128). detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT03157128 Phase I LOXO-292 Phase 1 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET-Fusion Lung Cancer and Medullary Thyroid Cancer Recruiting